Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.38 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3948254 | 1.00 | GSR (0.50) | GSRCPB2RNPEPUSP2SLCO1B1 | |
| SCHEMBL2824475 | 1.00 | GSR (0.50) | GSRCPB2RNPEPUSP2SLCO1B1 | |
| SCHEMBL16732008 | 1.00 | GSR (0.50) | GSRCPB2RNPEPUSP2SLCO1B1 | |
| SCHEMBL358290 | 1.00 | GSR (0.50) | GSRCPB2RNPEPUSP2SLCO1B1 | |
| Hydrochloric Acid SCHEMBL16760214 | 0.98 | GSR (0.48) | GSRCPB2RNPEPUSP2SLCO1B1 | |
| Hydrochloric Acid SCHEMBL16760213 | 0.98 | GSR (0.48) | GSRCPB2RNPEPUSP2SLCO1B1 | |
| Hydrochloric Acid SCHEMBL7107024 | 0.96 | GSR (0.47) | GSRCPB2RNPEPUSP2SLCO1B1 | |
| Hydrochloric Acid SCHEMBL751303 | 0.96 | GSR (0.47) | GSRCPB2RNPEPUSP2SLCO1B1 | |
| SCHEMBL16731992 | 0.86 | USP2 (0.46) | GSRCPB2RNPEPUSP2SLCO1B1 | |
| SCHEMBL2482513 | 0.86 | USP2 (0.46) | GSRCPB2RNPEPUSP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250381249-A1 | COMBINATION TREATMENT FOR RESISTANT HYPERTENSION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-12-18 | — | — | US | disclosed |
| WO-2025235379-A1 | POLYPEPTIDES HAVING NATRIURETIC AND INSULIN-SECRETING ACTIONS, AND METHODS FOR THEIR USE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025226690-A1 | METHODS AND MATERIALS FOR USING GC-A RECEPTOR ACTIVATING PEPTIDES IN COMBINATION WITH GLP-1/GIP RECEPTOR AGONISTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12427185-B2 | Formulations of MANP and uses thereof | E-Star Biotech, LLC (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250295730-A1 | METHODS AND MATERIALS FOR MODULATING T CELL ACTIVATION USING TRAILshort POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-09-25 | — | — | US | disclosed |
| EP-4603090-A1 | COMBINATION TREATMENT FOR RESISTANT HYPERTENSION | Mayo Foundation for Medical Education and Research (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4595970-A2 | MANP ANALOGUES | Mayo Foundation for Medical Education and Research (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12371461-B2 | Nemo coiled coil mimics and methods of using same | NEW YORK UNIVERSITY (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3877402-B1 | COMBINATION TREATMENT FOR HYPERTENSION | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-07-16 | — | — | EP | disclosed |
| EP-1420806-A2 | TRIPLE POLYPEPTIDE COMPLEXES | Arexis AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| EP-1131297-B1 | CERTAIN SUBSTITUTED CAPROLACTAMS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN TREATING TUMORS | NOVARTIS AG (CH) | 2004-04-14 | — | — | EP | disclosed |
| US-20030148944-A1 | Triple polypeptide complexes | AREXIS AB (SE) | 2003-08-07 | — | — | US | disclosed |
| US-6599898-B2 | Selected from the group consisting of breast, lung, non-small cell lung, osteolytic, colon and prostate | NOVARTIS AG (CH) | 2003-07-29 | — | — | US | disclosed |
| US-6555533-B2 | Specific antitumor activity against breast, colon, lung, prostate cancers and melanomas | NOVARTIS AG (CH) | 2003-04-29 | — | — | US | disclosed |
| US-20030055041-A1 | Certain substituted caprolactam carbonates and ethers, pharmaceutical compositions containing them and their use in treating tumors | KINDER FREDERICK RAY (US) | 2003-03-20 | — | — | US | disclosed |
| WO-2003006603-A2 | TRIPLE POLYPEPTIDE COMPLEXES | AREXIS AB (SE) | 2003-01-23 | — | — | WO | disclosed |
| US-6413954-B1 | 3,4,5-TRIHYDROXY-2-METHOXY-8,8-DIMETHYL-N-((3,6)-HEXAHYDRO-2 -OXO-6-(((DECYLOXY)CARBONYL)OXY)-2H-AZEPIN-3-YL)NON-6-ENON-AMIDES; SYNTHESIS BY ACYLATION AND HYDROLYSIS; HIGHER SELECTIVITY IN KILLING CANCER CELLS; CHEMOTHERAPY | NOVARTIS AG (CH) | 2002-07-02 | — | — | US | disclosed |
| US-20010044433-A1 | Use of certain substituted caprolactams in treating tumors | NOVARTIS AG (CH) | 2001-11-22 | — | — | US | disclosed |
| US-6239127-B1 | CHEMOTHERAPY OF TUMORS, EXHIBIT A HIGH DEGREE OF SELECTIVITY IN KILLING CANCER CELLS. | NOVARTIS AG (CH) | 2001-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371461-B2 | Nemo coiled coil mimics and methods of using same | COIL, CALCOCO2, NCAPH | GSR 4010/4885CPB2 727/4885RNPEP 4529/4885 |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | DDX21, PHAX, RBX1 | GSR 3492/4885CPB2 2297/4885RNPEP 4478/4885 |
| US-20030055041-A1 | Certain substituted caprolactam carbonates and ethers, pharmaceutical compositions containing them and their use in treating tumors | VHL, CAPRIN1, CAPN9 | GSR 4131/4885CPB2 3380/4885RNPEP 3656/4885 |
| US-20010044433-A1 | Use of certain substituted caprolactams in treating tumors | VHL, TP53, CAPRIN1 | GSR 3032/4885CPB2 2521/4885RNPEP 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.